Document Detail

New approaches to the pharmacological management of generalized anxiety disorder.
MedLine Citation:
PMID:  23282069     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Selective serotonin reuptake inhibitors (SSRIs) and serotonine reuptake Inhibitors (SNRIs) together with pregabalin are actually considered by international guidelines as the first-line choice for generalized anxiety disorder (GAD) treatment. However, 50% of GAD patients have poor response to first-line treatments and different molecules, such as atypical antipsychotics and mood stabilizers, have been used for treating this condition. Purpose of the present article is to provide an overview of the most recent pharmacological approaches for the treatment of GAD and the rationale for their use.
AREAS COVERED: A research in the main database sources has been conducted to obtain an overview of the new pharmacological approaches in GAD (anticonvulsants, atypical antipsychotics, agomelatine, memantine, ondansetron and riluzole).
EXPERT OPINION: Among unlabelled molecules, quetiapine seems to have the most robust evidence of efficacy in GAD. Valproic acid and agomelatine appear to be effective in GAD patients, but the data are preliminary and need to be confirmed by future studies. Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects. Future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.
Massimiliano Buoli; Alice Caldiroli; Elisabetta Caletti; Riccardo Augusto Paoli; Alfredo Carlo Altamura
Related Documents :
23070149 - Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 3...
23793559 - Pervasive refusal syndrome (prs) 21 years on: a re-conceptualisation and a renaming.
23633929 - Bereavement by traumatic means: the complex synergy of trauma and grief.
22938169 - Sleep apnea risk and clinical correlates in patients with bipolar disorder.
22517799 - Developmental macular disorders: phenotypes and underlying molecular genetic basis.
24012079 - Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and...
6682529 - Spontaneous oral-facial dyskinesia: neuropathology of a case.
12589879 - A preliminary morphometric magnetic resonance imaging study of regional brain volumes i...
23827249 - Autoinflammatory syndromes.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-03
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  14     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-06-27     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-84     Citation Subset:  IM    
University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Department of Psychiatry, Via F. Sforza 35, 20122, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Anxiety Agents / pharmacology,  therapeutic use*
Anxiety Disorders / drug therapy*,  physiopathology
Evidence-Based Medicine
Models, Biological
Molecular Targeted Therapy
Practice Guidelines as Topic*
Treatment Outcome
Reg. No./Substance:
0/Anti-Anxiety Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of sugar beet genotype on the Beet necrotic yellow vein virus P25 pathogenicity factor and ev...
Next Document:  Disease gene identification by random walk on multigraphs merging heterogeneous genomic and phenotyp...